Clinical trial NCT03293563: UroCCR Database: French Research Network for Kidney Cancer
Official title: UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Kidney Cancer
Keywords: Kidney cancer
Surgical approaches
Medical treatment
Multicentric and multidisciplinary network
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2017-09-26
Enrollment: 30000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Kidney cancer

Brief summary: Within the framework for kidney cancer care, with the recent diversification of treatment modalities of these tumors and the deployment of the concept of multidisciplinary team, it was considered necessary to adapt the research tools to reality of health-care for patients with kidney cancer.

UroCCR is the French research network for kidney cancer, funded by the French National Cancer Institute as part of the call for projects for clinical and biological databases (BCB). Depending on the case presentation and disease evolution, more than a thousand of different variables can be recorded. At the same time, biological samples (plasma, urine, healthy and tumor tissues) are collected.

This database contains a considerable number of information and high added value since it is the result of multiple expertises that make it not only a multidisciplinary tool but also multicenter, allowing fundamental, translational and clinical research.

Detailed description: The UroCCR database is a national medico-scientific network focused on therapeutic management and applied research in kidney cancer.

Secondary objectives:

1. - Evaluate and compare different surgical approaches in the treatment of kidney cancer,
2. - Evaluate and compare safety/efficacy of different drugs in the treatment of kidney cancer.

Eligibility criteria: Inclusion Criteria:

* Adult patient with kidney cancer
* Patient with no opposition to collection of its data for the study

Exclusion Criteria: none

Primary outcomes:
measure: Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Secondary outcomes:
measure: Dosage of creatininemia to assess the renal function after surgery
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Dosage of MDRD GFR to assess the renal function after surgery
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Safety and efficacy of medical treatment on kidney tumor size evolution
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Safety and efficacy of medical treatment on biological parameters
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
measure: Progression of the tumor
timeFrame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU Angers
city: Bordeaux
country: France
facility: CHU Bordeaux
city: Bordeaux
country: France
facility: Clinique TIVOLI-DUCOS
city: Cabestany
country: France
facility: Polyclinique Médipôle Saint-Roch_Cabestany
city: Caen
country: France
facility: CHU Caen
city: Clermont-Ferrand
country: France
facility: CHU de Clermont-Ferrand
city: Corbeil-Essonnes
country: France
facility: Ch Sud Francilien
city: Créteil
country: France
facility: CHU Henri Mondor - APHP
city: Dijon
country: France
facility: CHU de Dijon
city: Fontainebleau
country: France
facility: CH du Sud Seine et Marne
city: La Tronche
country: France
facility: CHU Grenoble
city: Le Mans
country: France
facility: Pôle Santé Sud
city: Libourne
country: France
facility: CH Libourne
city: Lille
country: France
facility: CHRU Lille - Centre Oscar Lambret
city: Lille
country: France
facility: Hôpital privé La Louvière
city: Limoges
country: France
facility: CHU Limoges
city: Lyon
country: France
facility: HCL Lyon
city: Marseille
country: France
facility: APH Marseille
city: Marseille
country: France
facility: Institut Paoli-Calmette
city: Mont-de-Marsan
country: France
facility: CH Mont de Marsan
city: Montauban
country: France
facility: Clinique du Pont de Chaume
city: Nancy
country: France
facility: CHRU de Nancy
city: Nantes
country: France
facility: CHU de Nantes
city: Nice
country: France
facility: CHU de Nice
city: Nice
country: France
facility: Clinique Saint George
city: Nîmes
country: France
facility: CHU de Nîmes
city: Paris
country: France
facility: CHU Kremlin Bicêtre - APHP
city: Paris
country: France
facility: CH St Joseph
city: Paris
country: France
facility: Hôpital Européen Georges Pompidou - APHP
city: Paris
country: France
facility: CHU Tenon - APHP
city: Paris
country: France
facility: Hôpital Bichat -APHP
city: Paris
country: France
facility: Hôpital Cochin Port-Royal - APHP
city: Paris
country: France
facility: Hôpital Pitié Salpétrière - APHP
city: Plérin
country: France
facility: Hôpital privé des Côtes d'Armor
city: Poitiers
country: France
facility: CHU Poitiers
city: Périgueux
country: France
facility: Polyclinique Francheville
city: Quincy-sous-Sénart
country: France
facility: Hôpital privé Claude Galien
city: Quint-Fonsegrives
country: France
facility: Clinique La Croix Du Sud
city: Reims
country: France
facility: CHU Reims
city: Rennes
country: France
facility: CHU Rennes - Centre Eugène Marquis
city: Rouen
country: France
facility: CHU Rouen
city: Saint-Herblain
country: France
facility: Clinique Santé Atlantique de Nantes
city: Saint-Herblain
country: France
facility: Clinique Urologique Nantes Atlantis
city: Saint-Étienne
country: France
facility: CHU St-Etienne
city: Strasbourg
country: France
facility: CHU Strasbourg
city: Strasbourg
country: France
facility: ICANS
city: Toulouse
country: France
facility: CHU Toulouse - Centre Claudius Régaud
city: Toulouse
country: France
facility: Clinique Pasteur
city: Tours
country: France
facility: CHRU Tours
city: Kourou
country: French Guiana
facility: Centre Hospitalier de Kourou
Study officials:
affiliation: University Hospital, Bordeaux
name: Jean-Christophe BERNHARD, PHU
role: PRINCIPAL_INVESTIGATOR
References:
citation: Brehier G, Bouvier A, Besnier L, Willoteaux S, Nedelcu C, Culty T, Aube C, Bigot P. Renal function after partial nephrectomy following intra-arterial embolization of renal tumors. Sci Rep. 2020 Dec 7;10(1):21352. doi: 10.1038/s41598-020-78461-5.